antibody

p16INK4a antibody

MBS831417

0.1 mg

665 USD

monoclonal

mouse

nonconjugated

1H4

human, mouse

western blot, immunohistochemistry, immunoprecipitation

Antibody

p16INK4a antibody

p16INK4a

Monoclonal p16; Anti-p16; CDKNA 2; p16INK4A; CDKNA-2; CDK4I; MTS-1; Cyclin-dependent kinase inhibitor 2A isoforms 1/2/3; Cyclin-dependent kinase 4 inhibitor A; Multiple tumor suppressor 1; CDKN2A; p16-INK4; p16-INK4a

p16INK4a, partial; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A; Cyclin-dependent kinase 4 inhibitor A; CDK4I; p16-INK4a; p16-INK4

p16INK4a

Cdkn2a; Cdkn2a; Arf; p16; MTS1; Pctr1; p19ARF; p16INK4a; p19 ARF ARF-INK4a; INK4a-ARF; Ink4a/Arf; p16(INK4a); CDK4I; p16-INK4

CDN2A_MOUSE

Monoclonal

IgG1

1H4

Mouse

Human

155

p16INK4a antibody was purified with protein A

Lyophilized product from 1% BSA in PBS containing 0.05% NaN3, reconstitute with 1 ml of distilled water

100ug Lyophilized

Store at 4 degree C until reconstitution. Following reconstitution aliquot and freeze at 20 degree C for long term storage

Immunohistochemistry (IHC), Western Blot (WB), Immunoprecipitation (IP)

IHC: 5 ug/ml. IP: 2 ug/ml. WB: 1 ug/ml

Source Note: Supernatant. Biological Significance: p16INK4a is a cyclin-dependent kinase (CDK) inhibitor, and binds CDK4 and CDK6 inhibiting their kinase activity. It is also called MTS1 and INK4a, and p15INK4b (MTS2), p18INK4c, and p19INK4d are other members of the INK4 family. p16INK4a is a tumor suppressor gene, and inactivation is seen in many cancer tissues and cancer cell lines as a result of mutations or hypermethylation. However, overexpression of p16INK4a has been reported in several tumors, including cervical cancer. Infection with human papilloma virus (HPV) has been suggested to play a large role in the development of cases of cervical cancer. Assessment of overexpression of p16INK4a by immunohistochemistry methods has been shown to be more useful in the diagnosis of cervical dysplasia than existing methods of detection of high-risk-group HPV infection.

Immunogen: P16INK4A antibody was raised in mouse using recombinant human p16 as the immunogen

Cell Cycle & Cell Death

Mouse monoclonal Human p16INK4a antibody

1762924

AAB39600.1

19,238 Da

Apoptosis Pathway (198339); Bladder Cancer Pathway (83308); Bladder Cancer Pathway (527); Cell Cycle Pathway (83251); Cell Cycle Pathway (198407); Cell Cycle Pathway (463); Cell Cycle Signaling Pathway (522974); Chronic Myeloid Leukemia Pathway (83309); Chronic Myeloid Leukemia Pathway (528); G1 To S Cell Cycle Control Pathway (198334)

p16-INK4A: a cell-cycle regulatory protein that interacts with CDK4 and CDK6, inhibiting their ability to interact with cyclins D. Inhibits the phosphorylation of the retinoblastoma protein by CDK4 or CDK6, and entry into the S phase of the cell cycle. The p16INK4A and p14ARF proteins are encoded by CDKN2A, a known tumour suppressor gene in multiple cancers. CDKN2A is inactivated in 72% of cases of lung squamous cell carcinoma: 21% by epigenetic silencing by methylation, 18% inactivating mutation, 4% by exon 1b skipping, and 29% by homozygous deletion. Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome, Li-Fraumeni syndrome, and the melanoma-astrocytoma syndrome. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. Four alternatively spliced p16 isoforms have been reported. Two alternatively spliced isoforms of ARF have been reported. Protein type: Tumor suppressor; Cell cycle regulation; Nucleolus. Cellular Component: nucleoplasm; nuclear body; granular component; protein complex; mitochondrion; cytoplasm; nucleolus; nucleus. Molecular Function: cyclin-dependent protein kinase inhibitor activity; NF-kappaB binding; protein binding; DNA binding; p53 binding; ubiquitin-protein ligase inhibitor activity; transcription factor activity; transcription factor binding; protein kinase binding. Biological Process: epidermis development; protein polyubiquitination; somatic stem cell maintenance; apoptosis; positive regulation of apoptosis; positive regulation of transcription, DNA-dependent; positive regulation of apoptosis involved in mammary gland involution; regulation of protein stability; negative regulation of B cell proliferation; glucose homeostasis; response to organic cyclic substance; negative regulation of cell cycle; regulation of protein export from nucleus; negative regulation of cell proliferation; apoptotic mitochondrial changes; regulation of transcription, DNA-dependent; regulation of G2/M transition of mitotic cell cycle; somatic stem cell division; negative regulation of protein binding; cell cycle arrest; aging; negative regulation of immature T cell proliferation in the thymus; caspase activation; response to drug; transcription, DNA-dependent; protein destabilization; protein stabilization; negative regulation of cyclin-dependent protein kinase activity; cell aging; cell cycle; negative regulation of cell-matrix adhesion; response to organic nitrogen; negative regulation of mammary gland epithelial cell proliferation; rRNA transcription; positive regulation of protein sumoylation; regulation of gene expression; inhibition of NF-kappaB transcription factor; regulation of nucleocytoplasmic transport; negative regulation of ubiquitin-protein ligase activity; negative regulation of phosphorylation; negative regulation of protein kinase activity; positive regulation of transcription factor activity; positive regulation of transcription from RNA polymerase II promoter; negative regulation of cell growth; positive regulation of DNA damage response, signal transduction by p53 class mediator; regulation of cyclin-dependent protein kinase activity; negative regulation of transcription, DNA-dependent; rRNA processing; G1/S transition of mitotic cell cycle

0.1 mg

665 USD